Evidence map›Paper›PMID 42205691›Full record

ArticleiScience2026

Enhanced efficacy of gastric cancer treatment by a combination of NK cells and chemotherapy.

Jingjing Yue, Jie Ma, Yangyang Li, Hongbo Dong, Yongge He, Minhua Chen, Fang Fang, Weihua Xiao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jingjing YueKey Laboratory of Immune Response and Immunotherapy, The First Affiliate Hospital of USTC, Division of Life Sciences and Medicine, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, Anhui 230021, China.
Jie MaKey Laboratory of Immune Response and Immunotherapy, The First Affiliate Hospital of USTC, Division of Life Sciences and Medicine, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, Anhui 230021, China.
Yangyang LiKey Laboratory of Immune Response and Immunotherapy, The First Affiliate Hospital of USTC, Division of Life Sciences and Medicine, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, Anhui 230021, China.
Hongbo DongKey Laboratory of Immune Response and Immunotherapy, The First Affiliate Hospital of USTC, Division of Life Sciences and Medicine, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, Anhui 230021, China.
Yongge HeKey Laboratory of Immune Response and Immunotherapy, The First Affiliate Hospital of USTC, Division of Life Sciences and Medicine, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, Anhui 230021, China.
Minhua ChenKey Laboratory of Immune Response and Immunotherapy, The First Affiliate Hospital of USTC, Division of Life Sciences and Medicine, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, Anhui 230021, China.
Fang FangKey Laboratory of Immune Response and Immunotherapy, The First Affiliate Hospital of USTC, Division of Life Sciences and Medicine, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, Anhui 230021, China.
Weihua XiaoKey Laboratory of Immune Response and Immunotherapy, The First Affiliate Hospital of USTC, Division of Life Sciences and Medicine, School of Basic Medical Sciences, University of Science and Technology of China, Hefei, Anhui 230021, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NK cells demonstrate potent antitumor activity but show limited efficacy in gastric cancer (GC) due to poor tumor infiltration and dysfunction. To overcome this, we investigated the therapeutic potential of combining NK cell (expanded from healthy donor PBMCs) with chemotherapy (oxaliplatin + fluorouracil).

Indexed as

biological sciencescancertherapy

Identifiers

PMID42205691
PMCPMC13206747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.